Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Agios Pharmaceuticals, Inc. (AGIO : NSDQ)

• Company Description    Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases. Number of Employees: 393

• Price / Volume Information    Yesterday's Closing Price: $25.71 Daily Weekly Monthly 20 Day Moving Average: 417,599 shares Shares Outstanding: 55.58 (millions) Market Capitalization: $1,428.98 (millions) Beta: 0.94 52 Week High: $34.76 52 Week Low: $16.75 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.43% 0.47% 12 Week 13.76% 5.60% Year To Date -8.44% -16.72%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 88 SIDNEY STREET - CAMBRIDGE,MA 02139 USA ph: 617-649-8600 fax: - investors@agios.com http://www.agios.com

• General Corporate Information    Officers Brian Goff - Chief Executive Officer Jacqualyn A. Fouse - Chair of the Board of Directors Cecilia Jones - Chief Financial Officer T.J. Washburn - Vice President; Controller Rahul Ballal - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 00847X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/03/23 Share - Related Items Shares Outstanding: 55.58 Most Recent Split Date: (:1) Beta: 0.94 Market Capitalization: $1,428.98 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.58 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-6.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 9.77% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.38 Price/Cash Flow: - Price / Sales: 75.14 EPS Growth vs. Year Ago Period: 15.52% vs. Previous Quarter: -319.40% Sales Growth vs. Year Ago Period: 574.16% vs. Previous Quarter: 30.14% ROE 03/31/23 - -20.23 12/31/22 - -20.68 09/30/22 - -31.40 ROA 03/31/23 - -18.08 12/31/22 - -18.52 09/30/22 - -28.19 Current Ratio 03/31/23 - 17.55 12/31/22 - 13.30 09/30/22 - 14.65 Quick Ratio 03/31/23 - 17.30 12/31/22 - 13.16 09/30/22 - 14.55 Operating Margin 03/31/23 - -1,146.58 12/31/22 - -1,627.82 09/30/22 - - Net Margin 03/31/23 - -1,146.58 12/31/22 - -1,627.82 09/30/22 - - Pre-Tax Margin 03/31/23 - -1,146.58 12/31/22 - -1,627.82 09/30/22 - -3,694.98 Book Value 03/31/23 - 18.65 12/31/22 - 20.03 09/30/22 - 19.11 Inventory Turnover 03/31/23 - 0.26 12/31/22 - 0.34 09/30/22 - 0.44 Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©